Advanced-Stage Chronic Myeloid Leukemia: Options for Difficult Treatment Situations

Area of Science:

• Hematology
• Oncology
• Leukemia Research

Background:

• Chronic myeloid leukemia (CML) can progress to aggressive accelerated phase (AP) or blast phase (BP) in 4-7% of patients.
• BP-CML is often myeloid but can be lymphoid lineage.
• Treatment decisions are complicated by the rarity of AP/BP-CML, limited clinical trial data, and evolving diagnostic classifications.

Purpose of the Study:

• To review existing data on therapeutic approaches for patients with accelerated phase (AP) and blast phase (BP) chronic myeloid leukemia (CML).

Main Methods:

• Retrospective chart reviews and analysis of data from early tyrosine kinase inhibitor (TKI) studies.
• Examination of evolving diagnostic criteria for AP/BP-CML, including World Health Organization (WHO) and International Consensus Classification (ICC) definitions.
• Assessment of factors influencing therapy, such as prior treatment, BCR::ABL1 mutations, comorbidities, cell lineage, and allogeneic stem cell transplantation (alloHCT) eligibility.

Main Results:

• AP-CML at presentation may have a favorable prognosis without alloHCT if responsive to therapy.
• For TKI-refractory AP-CML or any BP-CML, alloHCT is the primary curative option.
• Therapeutic strategies are individualized based on multiple patient- and disease-specific factors.

Conclusions:

• Optimal management of AP/BP-CML requires careful consideration of patient-specific factors and available treatment options.
• Allogeneic stem cell transplantation remains a critical curative modality for advanced CML phases.
• Further research is needed to establish evidence-based guidelines for these rare CML subtypes.